Buckets of money for the brain
By Michael J. Haas, Associate Editor, and Kai-Jye Lou, Senior Writer
Apart from the recent ALS ice-bucket challenge, the perception is that neurological disorders have become the poor relation of oncology and other diseases when it comes to public and private funding. But an uptick in activity on both fronts suggests the landscape of neuroscience investment may not be as bleak as presumed. Although many researchers contend that the field is still underfunded relative to the burden of disease on society, advances in genetics, markers and disease models-as well as multidisciplinary projects focusing on the brain as a whole-are drawing investors back and prompting the creation of public-private partnerships (PPPs) that might spur yet more innovation.
Indeed, this week, the Janssen Inc. unit of Johnson & Johnson announced a partnership with the University of Toronto to fund new therapeutic approaches in mood disorders and Alzheimer's disease (AD). The deal is the 22nd neurology-based PPP this year and continues the trend of the last 3 years in which 29-57 neurology PPPs were formed annually. When that trend is compared with a range of 49-79 PPPs annually over the same period for cancerwidely considered the best-funded disease area-it suggests interest in neuroscience has not faded entirely (see Figure 1 .I, "Investing in the brain"). Moreover, there were more PPPs focused on neurology than on endocrine and metabolic diseases or autoimmunity and inflammation each year between 2011 and 2013. 1 The Janssen-University of Toronto collaboration, dubbed Neuroscience Catalyst, is designed to foster data that can attract funding and spawn new companies, said Guy Seabrook, VP of neuroscience innovation at J&J's California Innovation Center. He added that the emphasis is on asset-based opportunities such as candidate therapeutics rather than animal m o d e l s , b u t t h e partners also want to fund disruptive technologies that can create value in terms of business enterprises.
The collaboration is structured along the no-strings-attached mo d el of Janss e n L ab s b e c au s e t h e company wants to seed ideas coming out of academia without hampering entities with respect to IP rights and other commercial issues, said Seabrook. J&J is one of the pharmas that have kept up research in neurological disease, and Seabrook said the new partnership will complement, not replace, internal programs.
Despite the retreat by some pharmas from neurological R&D, venture investment in the field lags behind oncology by only 50%. From 2011 to 2013, seed and series A investments in neurology companies ranged from $170 million to $235 million annually-with another $88 million invested through the end of August 2014 (see Figure 1 .II, "Investing in the brain").
"I think it's a great time for early stage neuroscience investing," Bruce Booth, partner at Atlas Venture, told SciBX. "Some exciting new opportunities are arising from a confluence of trends, such as genetic insights into neurological diseases or disease subsets, improved understanding of preclinical models, and better imaging and biomarker modalities. " He added, "Also, importantly, in the clinical arena the ability to dissect heterogeneous disease populations into various subpopulations should enable better trial outcomes and quicker paths to proof of concept. "
Booth said these trends have tipped the balance at Atlas heavily in neuroscience's favor. "Of the 30 active portfolio companies across our last 3 funds, at least 13 of the companies-roughly 40%-are dedicated to or have pipeline programs in a variety of "Disability created by mood disorders-depression and bipolar disorder-have a huge impact on society. Also, the standard of care only works in a subset of patients and has a long delay of onset. There is good work going on now that shows these issues are addressable." TRANSLATIONAL NOTES neuroscience fields such as Alzheimer's disease, Parkinson's disease, psychiatry, pain, ataxia and orphan neuroscience diseases. Since only about 14% of industry's pipeline is in neuroscience, we are significantly overweight in neuroscience and bullish given our portfolio exposure. " The PPPs formed between 2011 and July 2014 showed a similar focus on those indications. AD, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), schizophrenia-related indications and pain have received the greatest attention. A further 50 PPPs were created for unspecified or multiple indications (see Figure 2 , "Neurology indications for PPPs formed since 2011").
-Guy Seabrook, Johnson & Johnson
Booth was not surprised that the disease-specific deals and PPPs have clustered around AD, PD and pain because of the massive disease burden and unaddressed morbidity of those three diseases. He added, "I am pleasantly surprised to see the ALS numbers as high as they are. "
By contrast, anxiety and depression together represent only about 2% of the total number of partnerships. Seabrook said J&J's Neuroscience Catalyst chose mood disorders-which include depression-as a principal focus because of the very large disease burden despite the plethora of approved drugs.
"Disability created by mood disorders-depression and bipolar disorder-have a huge impact on society. Also, the standard of care only works in a subset of patients and has a long delay of onset. There is good work going on now that shows these issues are addressable," he said.
A clearer burden
Magali Haas, founder and CEO of Orion Bionetworks Inc., told SciBX that part of the reason for increased investment is that the burden of neurological diseases on society is becoming clearer and more widely known.
Orion is a not-for-profit organization that creates alliances among its network of partners to accelerate treatments for brain disorders.
The best estimate puts the costs of neurological diseases in the U.S. at $1 trillion annually, she said. "In 2011, the European Brain Council looked at 19 categories of brain disorders in 27 countries and estimated that 1 in 5 people would be affected by a brain disorder at some point in their lives, with a total cost of $1 trillion annually. "
Haas said these figures likely underestimate the disease burden in the U.S. and EU because most of the data come from associations and foundations focused on specific indications, so the costs of some disorders and comorbidities are not reflected in the estimates for neurological disease as a whole.
She added, "We are seeing a new focus on getting a better handle on the aggregate costs of neurological diseases through efforts by the EU, G7 countries and other international organizations. "
Haas also noted that Horizon 2020-a 7-year, €80 billion ($103.5 billion) funding program in the EU-has put neuroscience at the top of its agenda "because of the huge societal impact of these disorders-which exceeds the impact of cancer, diabetes and cardiovascular disease combined. "
These are among the factors that led to the Human Brain Project in the EU and the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative in the U.S., Haas said.
But she argued that the investment still does not match the need. "Historically, the NIH invests about $5.5 billion in neuroscience, and 
ANALYSIS
TRANSLATIONAL NOTES She noted that Brain Canada's whole-brain approach does not discourage research on one disease but instead encourages researchers to think about how one disease might connect to others. "Questions about a specific disease are asked in a broader context. "
According to Jabalpurwala, the hands-off approach of the Canadian government enables Brain Canada to take the kind of risks that are going to be needed to advance the field. "Everything we fund with our dollars is matched by government dollars and has to be linked to an outcome, " she said. "The Canadian government provides leadership by funding basic research, then partners with Brain Canada and other organizations to bring in the outcomes-oriented piece. " "Our donors and partners have interest in certain disease areas. But exactly where the funding goes is determined by the project proposals we receive. We take risks on solid ideas from solid research teams," she said.
Through the Canada Brain Research Fund, Brain Canada has committed to raising C$100 million ($91.7 million) from private and nongovernmental sources that will be matched on a 1:1 basis by the Canadian government. The 5-year fund was announced in the federal budget in 2011 and launched in 2012.
